BrightSpring Health Services, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTSG research report →
Range $70 – $92
Price Chart
About the company
BrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical provider services, including both clinical care and supportive assistance, to individuals covered by Medicare, Medicaid, and private insurance.
- CEO
- Jon Rousseau
- IPO
- 2024
- Employees
- 23,500
- HQ
- Louisville, KY, US
AI snapshot
Six angles, distilled from the data.
The stock is in a strong multi-month uptrend and still trades above its 200-day moving average, with the 50-day also above the long-term trend. It sits well off the 52-week low and closer to the upper half of its yearly range, though not at the high, which keeps the setup constructive rather than stretched.
Street sentiment is firmly positive: 13 buys and no holds or sells, with a consensus Buy and an average target of $82.64 versus a recent close in the mid-60s. Recent target work has trended higher, with UBS at $92, Goldman Sachs at $90, and BMO, Guggenheim, and others reaffirming upbeat views.
The earnings profile remains clean, with 8 straight EPS beats and recent surprises of 20.0%, 21.6%, and 25.8%. Next-year EPS estimates point to $2.4293 from a $1.41 TTM base, so shareholders should watch whether revenue growth and margin expansion keep supporting that step-up.
The pattern is mixed but leans to net selling, driven by large 10% owner disposals and one officer sale. Most other filings are automatic or non-discretionary items such as in-kind transfers, awards, and exempt transactions, so the main signal is the sizable KKR exit activity rather than routine insider noise.
Profitability is solid for a healthcare services platform, with a 12.5% gross margin, 3.51% operating margin, and 2.69% net margin. Growth is still strong, with revenue up 26.4% year over year and earnings up 82%, while free cash flow reached $585.7 million in 2025.
BTSG screens as a faster-growing healthcare services name than many peers, supported by double-digit revenue growth and consistent earnings beats. The valuation remains rich at 37.44x earnings, so the market is paying for execution and continued estimate revisions.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.50B
- P/E
- 41.67
- Fwd P/E
- 32.70
- PEG
- 0.27
- P/S
- 0.89
- P/B
- 6.50
- EV/EBITDA
- 21.52
- Div Yield
- 0.00%
- Gross Margin
- 12.50%
- Op Margin
- 3.61%
- Net Margin
- 2.22%
- ROE
- 16.75%
- ROIC
- 9.83%
Latest fiscal year · YoY change
- Revenue
- $12.91B+14.6%
- Gross Profit
- $1.52B-4.4%
- Op Income
- $295.25M
- Net Income
- $190.67M+1155.6%
- EPS
- $0.94+1104.3%
- OCF Growth
- +1961.8%
- FCF Growth
- +790.7%
- 52W High
- $73.75
- 52W Low
- $32.72
- 50D MA
- $62.54
- 200D MA
- $56.78
- Beta
- 1.78
- RSI (14)
- 44
- Avg Volume
- 2.46M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BrightSpring delivered a strong Q3 with revenue, EBITDA, EPS, and cash flow all beating expectations, while raising 2026 guidance and reiterating confidence in continued growth into 2027.· October 30, 2026
- Q3 revenue was $4.2 billion, up 26% year over year, with adjusted EBITDA of $228 million, up 42%.
- Adjusted EPS was $0.54, up 80% year over year and 20% sequentially; operating cash flow was $204 million.
- Pharmacy Solutions and Provider Services both grew strongly, with Pharmacy revenue up 26% and Provider revenue up 31%.
- 2026 guidance was raised to $15.9 billion-$16.125 billion of revenue and $850 million-$860 million of adjusted EBITDA.
- Management reiterated at least 15% to 20% organic adjusted EBITDA growth in 2027, with growth expected to be more even across the year.
BrightSpring reported third-quarter 2026 revenue of $4.2 billion, up 26% year over year, adjusted EBITDA of $228 million, up 42%, and adjusted EPS of $0.54, up 80%. Company gross profit was $519 million, up 32%, and cash flow from operations was $204 million. Pharmacy Solutions revenue was $3.7 billion, up 26%, with segment EBITDA of $202 million, up 43%; Provider Services revenue was $481 million, up 31%, with segment EBITDA of $79 million, up 30%. For 2026, management raised guidance to revenue of $15.9 billion-$16.125 billion and adjusted EBITDA of $850 million-$860 million, implying 23.2% to 24.9% revenue growth and 37.6% to 39.3% adjusted EBITDA growth versus 2025. They also expect about $35 million of 2026 adjusted EBITDA contribution from the Amedisys/LHC acquired branches, at least $700 million of annual operating cash flow, and over $600 million of cash flow after CapEx and before debt paydown and share repurchases.
Jon Rousseau framed the quarter as another example of BrightSpring executing at a high level across a broad platform, with growth driven by patient reach, operational efficiency, and accretive M&A. He emphasized that the company’s services are aligned with durable health care demand trends and that the business is benefiting from scale, quality outcomes, and technology investments, including AI. His tone was confident and expansive, repeatedly stressing that growth is broad-based and that the company is positioned for continued opportunity across pharmacy, provider, and primary care.
Jennifer Phipps highlighted the hard numbers behind the quarter: revenue of $4.2 billion, gross profit of $519 million, adjusted EBITDA of $228 million, and adjusted EPS of $0.54. She noted Pharmacy Solutions EBITDA margin of 5.4% and Provider Services EBITDA margin of 16.4%, and she broke out home and community pharmacy revenue at $553 million, down 6% due mainly to about a $50 million IRA impact and customer exits. On the balance sheet, she said total debt was about $2.2 billion, cash was $718 million, net debt was $1.5 billion, and leverage was 1.79x; she also said year-to-date share repurchases were $120 million. She reiterated that annual operating cash flow should be at least $700 million and said the company is evaluating its capital structure heading into 2027.
Analysts focused on specialty pharmacy script growth, per-script economics, the pace and durability of new limited distribution drugs, and whether 2027 growth might be more back-end loaded because of generics. Management said it does not comment at the individual drug level, but said 2026 launches are outperforming 2025 launches and that the company expects similar year-over-year adjusted EBITDA growth rates through the quarters of 2027. Questions also covered M&A, where management said the pipeline is full, it is open to somewhat larger deals than recent tuck-ins, but would not consider partnership-style structures. Another key topic was home and community pharmacy; management said the IRA remains a headwind, but underlying growth is improving and the business is now again contributing to company growth.
The bull case from this call is that BrightSpring is growing fast across multiple businesses at once, not just from one temporary driver. Management said 2026 LDD launches are outperforming prior launches, provider services remains very strong, home and community pharmacy is recovering, and cash generation is robust. They also reiterated at least 15% to 20% organic adjusted EBITDA growth in 2027, suggesting confidence that the growth engine remains intact.
The main risks discussed were continued IRA pressure in home and community pharmacy, dependence on execution across a complex and highly operational business, and some uncertainty around how 2027 will unfold as generic launches and new therapy mix change over time. Management also acknowledged that some growth drivers are early in their ramp, such as AI investments and the REACH ACO, which they do not expect to meaningfully contribute until later periods. In M&A, Jon Rousseau also stressed that deals are hard and that the company is deliberate, which implies not every opportunity will convert into accretive growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 76.0%
- Shares Outstanding
- 198.98M
- Float Shares
- 151.26M
of shares held by institutions
437 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 26.83M | 0 |
| Blackrock, Inc. | 21.40M | ▼ 2.63M |
| Fmr LLC | 17.37M | ▲ 3.97M |
| Vanguard Group Inc | 12.53M | ▲ 2.93M |
| Invesco Ltd. | 12.01M | ▲ 67.90K |
| Vanguard Portfolio Management LLC | 8.89M | ▼ 1.06M |
| Price T Rowe Associates Inc | 8.34M | ▼ 1.56M |
| Vanguard Capital Management LLC | 7.56M | ▲ 246.30K |
| State Street Corp | 6.40M | ▲ 133.31K |
| Geode Capital Management, LLC | 5.62M | ▲ 437.48K |
| T. Rowe Price Investment Management, Inc. | 5.44M | ▼ 603.22K |
| American Century Companies Inc | 3.74M | ▲ 449.96K |
Held by 501 ETFs
Biggest fund positions in BTSG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 26, 26 | Hopper Jeffrey A. | other | 0 |
| Oct 26, 26 | Hopper Jeffrey A. | other | 0 |
| Oct 26, 26 | Hopper Jeffrey A. | other | 0 |
| Oct 25, 26 | ROUSSEAU JON B | other | 36,355 |
| Sep 14, 26 | Greenwell Scott A. | other | 11,973 |
| Sep 14, 26 | Greenwell Scott A. | sell | 15,099 |
| Sep 14, 26 | Greenwell Scott A. | other | 11,973 |
| Jul 25, 26 | ROUSSEAU JON B | other | 56,319 |
| Jun 20, 26 | Greenwell Scott A. | other | 2,487 |
| Jun 11, 26 | Shah Nigam H. | other | 4,013 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BTSG coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BTSG?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Does BrightSpring Health Services, Inc. (BTSG) Have the Potential to Rally 29.69% as Wall Street Analysts Expect?
zacks.com · Nov 20
BrightSpring (BTSG) Price Forecast: Inverse Head-and-Shoulders Signals Upside Potential
fxempire.com · Nov 19
Buy 5 Stocks at 52-Week High With More Upside for the Short Term
zacks.com · Nov 18
Best "Strong Buy" Stocks Trading Near Their Highs to Buy as the Nasdaq Falls
zacks.com · Nov 17
Healthcare Stocks Overtake Tech: 5 Strong Buys Combining Growth And Value
seekingalpha.com · Nov 17
BrightSpring Health Services, Inc. (BTSG) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Buy 5 Growth Stocks to Enhance Your Portfolio Returns in November
zacks.com · Nov 10
BTSG vs. CAI: Which Stock Should Value Investors Buy Now?
zacks.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice
